Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonelokimab in Active Psoriatic Arthritis (IZAR-2)
NCT06641089Phase 3Active, not recruiting
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Oct 2024
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 11
01
Overview
A Phase 3 trial of sonelokimab in psoriatic arthritis (PsA), sponsored by MoonLake Immunotherapeutics. Started Oct 2024; status: active, not recruiting.
02
Drugs
sonelokimab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06641089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06641089.